Last reviewed · How we verify
Icotinib Hydrochloride Tablets
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | Icotinib Hydrochloride Tablets |
|---|---|
| Also known as | Conmana |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Icotinib hydrochloride is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Anorexia
Key clinical trials
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (PHASE2, PHASE3)
- Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (PHASE2)
- Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI (NA)
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma (PHASE3)
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer (NA)
- Conmana Combined With Thalidomide to Treat NSCLC (PHASE4)
- Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |